MedTrace Logo

Transgender Cohort Study of Gender Affirmation and HIV-related Health

NCT03595956 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 4500

Last updated 2020-11-18

No results posted yet for this study

Summary

This observational research study will evaluate medical gender affirmation delivered in primary care as an intervention to reduce disparities in HIV-related outcomes (e.g., low rates of PrEP uptake for HIV-uninfected patients, high rates of viral suppression for HIV-infected patients) for transgender patients in two urban federally-qualified community health centers.

Conditions

  • HIV/AIDS
  • STI
  • Gender Dysphoria
  • Transsexualism
  • Gender Identity
  • Depression, Anxiety

Interventions

OTHER

Medical gender affirmation

The intervention to be evaluated is medical gender affirmation delivered in primary care (medical gender affirmation: hormones and/or surgery vs none).

Sponsors & Collaborators

  • Callen-Lorde Community Health Center

    collaborator OTHER

  • Patient-Centered Outcomes Research Institute

    collaborator OTHER

  • Fenway Community Health

    lead OTHER

Principal Investigators

  • Sari Reisner, ScD · Brigham and Women's Hospital & Harvard Medical School

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-02-11
Primary Completion
2020-12-31
Completion
2021-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03595956 on ClinicalTrials.gov